Sigrid Therapeutics takes in SEK 72 million in new capital
Swedish healthtech startup Sigrid Therapeutics is on its way to preventing two of the world's biggest health challenges, type 2 diabetes and obesity, with its SiPore15® powder.
-
-
Sigrid Therapeutics' silica-based biomaterial SiPore15 [® ] granted US patent for treatment and prevention of obesity and overweight
Sigrid Therapeutics, a technology company specializing in the prevention of type 2 diabetes and obesity, announced today that the company has been granted a patent by the United States Patent and Trademark Office (USPTO).
-
Sigrid Therapeutics selected to present results from the STAR Proof of Concept study at the American Diabetes Association's 80th Scientific Conference.
Sigrid Therapeutics (Sigrid) announced today that the results from the company’s STAR study have been selected for presentation at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2020.
-
Sigrid Therapeutics named by FierceMedTech as one of the "Fierce 15" companies in 2019 – the first Swedish winner ever
Sigrid Therapeutics announced today that the Company has been named by FierceMedTech as one of the 2019 “Fierce 15” companies, one of the most promising private medtech companies in the industry. This is the first time in its eight-year history that a Swedish company has been included on the list.
-
Sigrid Therapeutics one step closer to preventive treatment of type 2 diabetes
Sigrid Therapeutics reports significant blood sugar reduction and excellent safety profile in the STAR study with SiPore15, a groundbreaking medical device for prediabetes and untreated type 2 diabetes
-
Technology company Sigrid Therapeutics closes oversubscribed rights issue of SEK 15.5 million to accelerate market approval for groundbreaking blood sugar lowering product
Sigrid Therapeutics AB, an innovative technology company developing a new class of products to improve human health, including type 2 diabetes, today announces that it has closed a rights issue of SEK 15.5 million.
-
All patients treated in Sigrid Therapeutics' STAR clinical trial
Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies in metabolic diseases, today announces that all patients have completed treatment with SiPore15 in the STAR clinical trial.
-
Sigrid Therapeutic's CEO Sana Alajmovic on International High List of Young Life Science Innovators
The leading American life science magazine BioSpace has named Sana Alajmovic one of 10 young life science innovators under the age of 40 to watch in the future.
-
Sigrid Therapeutics - winner of Almi's pitch competition in connection with Almi's 10th anniversary
At Almi Invest's 10th anniversary on May 28 at Nalen in Stockholm, Sigrid's CEO and Co-Founder Sana Alajmovic won the jury and audience's favor in the Startup Pitch of the Year competition.
-
Sigrid Therapeutics CEO Sana Alajmovic selected to GEN's 2019 Top 10 Under 40
The leading international life science journal Genetic Engineering News (GEN) has selected Sana Alajmovic, CEO of Sigrid Therapeutics, to this year's highly prestigious Top 10 Under 40 list 2019.
-
New study on mice published in Nanomedicine shows that Sigrid's medical device product SiPore15 prevents weight gain
Sigrid Therapeutics today announced the publication of a large study in mice in the peer-reviewed journal Nanomedicine. The study demonstrates enzyme-blocking effects of mesoporous silica particles (MSPs) administered into the intestine with effects on food efficiency and metabolic risk factors as a result.